Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 May 11;312(7040):1187–1191. doi: 10.1136/bmj.312.7040.1187

Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial.

P Kelly 1, F Lungu 1, E Keane 1, R Baggaley 1, F Kazembe 1, J Pobee 1, M Farthing 1
PMCID: PMC2350957  PMID: 8634560

Abstract

OBJECTIVE--To determine the value of short course, high dose albendazole chemotherapy in the treatment of persistent diarrhoea related to HIV in unselected patients in urban Zambia. DESIGN--A randomised double blind placebo controlled trial of albendazole 800 mg twice daily for two weeks. Patients were monitored intensively for one month and followed for up to six months. SETTING--Home care. AIDS services in Lusaka and Ndola. PATIENTS--174 HIV seropositive patients with persistent diarrhoea (defined as loose but not bloody stools three or more times a day for three weeks or longer). No investigations were undertaken except HIV testing after counselling. MAIN OUTCOME MEASURES--Proportion of time periods during which diarrhoea was experienced after completion of treatment; proportion of patients with full remission after completion of treatment; mortality. RESULTS--The patients taking albendazole had diarrhoea on 29% fewer days than those taking placebo (P < 0.0001) in the two weeks after treatment. The benefit of albendazole was maintained over six months. In patients with a Karnofsky score of 50 to 70 (needing help with activities of daily living and unable to work, but not needing admission to hospital) diarrhoea was reduced by 50%. Remission was obtained in 26% of all patients who received albendazole (P = 0.004 against 9% receiving placebo), and this difference was maintained over six months (log rank test, P = 0.003). Albendazole had no effect on mortality. Minimal adverse effects were noted. CONCLUSIONS--For HIV infected Zambians with diarrhoea of more than three weeks' duration albendazole offers substantial relief from symptoms and may be used empirically, without prior investigation.

Full text

PDF
1187

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archibald L. K., Beeching N. J., Gill G. V., Bailey J. W., Bell D. R. Albendazole is effective treatment for chronic strongyloidiasis. Q J Med. 1993 Mar;86(3):191–195. [PubMed] [Google Scholar]
  2. Byar D. P., Schoenfeld D. A., Green S. B., Amato D. A., Davis R., De Gruttola V., Finkelstein D. M., Gatsonis C., Gelber R. D., Lagakos S. Design considerations for AIDS trials. N Engl J Med. 1990 Nov 8;323(19):1343–1348. doi: 10.1056/NEJM199011083231912. [DOI] [PubMed] [Google Scholar]
  3. Cali A., Kotler D. P., Orenstein J. M. Septata intestinalis N. G., N. Sp., an intestinal microsporidian associated with chronic diarrhea and dissemination in AIDS patients. J Eukaryot Microbiol. 1993 Jan-Feb;40(1):101–112. doi: 10.1111/j.1550-7408.1993.tb04889.x. [DOI] [PubMed] [Google Scholar]
  4. Chela C. M., Siankanga Z. C. Home and community care: the Zambia experience. AIDS. 1991;5 (Suppl 1):S157–S161. [PubMed] [Google Scholar]
  5. Colebunders R. L., Latif A. S. Natural history and clinical presentation of HIV-1 infection in adults. AIDS. 1991;5 (Suppl 1):S103–S112. [PubMed] [Google Scholar]
  6. Conlon C. P., Pinching A. J., Perera C. U., Moody A., Luo N. P., Lucas S. B. HIV-related enteropathy in Zambia: a clinical, microbiological, and histological study. Am J Trop Med Hyg. 1990 Jan;42(1):83–88. doi: 10.4269/ajtmh.1990.42.83. [DOI] [PubMed] [Google Scholar]
  7. Gazzard B., Blanshard C. Diarrhoea in AIDS and other immunodeficiency states. Baillieres Clin Gastroenterol. 1993 Jun;7(2):387–419. doi: 10.1016/0950-3528(93)90047-v. [DOI] [PubMed] [Google Scholar]
  8. Gilks C. F. The clinical challenge of the HIV epidemic in the developing world. Lancet. 1993 Oct 23;342(8878):1037–1039. doi: 10.1016/0140-6736(93)92885-w. [DOI] [PubMed] [Google Scholar]
  9. Kelly P., Buve A. Chemotherapy of African AIDS diarrhoea: a preliminary study. AIDS. 1993 Jan;7(1):91–93. doi: 10.1097/00002030-199301000-00014. [DOI] [PubMed] [Google Scholar]
  10. Lucas S. B., De Cock K. M., Hounnou A., Peacock C., Diomande M., Hondé M., Beaumel A., Kestens L., Kadio A. Contribution of tuberculosis to slim disease in Africa. BMJ. 1994 Jun 11;308(6943):1531–1533. doi: 10.1136/bmj.308.6943.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Meloni B. P., Thompson R. C., Reynoldson J. A., Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans R Soc Trop Med Hyg. 1990 May-Jun;84(3):375–379. doi: 10.1016/0035-9203(90)90324-8. [DOI] [PubMed] [Google Scholar]
  12. Molina J. M., Oksenhendler E., Beauvais B., Sarfati C., Jaccard A., Derouin F., Modaï J. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis. 1995 Jan;171(1):245–249. doi: 10.1093/infdis/171.1.245. [DOI] [PubMed] [Google Scholar]
  13. Mulder D. W., Nunn A. J., Kamali A., Nakiyingi J., Wagner H. U., Kengeya-Kayondo J. F. Two-year HIV-1-associated mortality in a Ugandan rural population. Lancet. 1994 Apr 23;343(8904):1021–1023. doi: 10.1016/s0140-6736(94)90133-3. [DOI] [PubMed] [Google Scholar]
  14. Piot P., Kapita B. M., Were J. B., Laga M., Colebunders R. L. AIDS in Africa: the first decade and challenges for the 1990s. AIDS. 1991;5 (Suppl 1):S1–S5. [PubMed] [Google Scholar]
  15. Shanson D. C. Septicaemia in patients with AIDS. Trans R Soc Trop Med Hyg. 1990;84 (Suppl 1):14–16. doi: 10.1016/0035-9203(90)90449-o. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES